44 Result(s)
-
Article
Open AccessSoluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.
-
Article
Open AccessElectrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
Extensive squamous cell carcinoma has few therapeutic options. In such cases, electrochemotherapy involving electroporation combined with antineoplastic drug appears to be a new potential option and may be con...
-
Article
Open AccessCOX-2 expression positively correlates with PD-L1 expression in human melanoma cells
The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is...
-
Article
Open AccessImmunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
-
Article
Open AccessMelanoma and immunotherapy bridge 2015
MELANOMA BRIDGE 2015
-
Article
Open AccessErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
-
Article
Open AccessDendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
-
Article
Open AccessAurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit tumor growth, suggesting a potential role in melanoma treatment.
-
Article
Open AccessUV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)
-
Article
Open AccessActivation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
-
Article
Open AccessAssessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma
-
Article
Open AccessLong-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
-
Article
Open AccessEfficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes (EAPs) suggest ipilimumab...
-
Article
Open AccessLong-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electroche...
-
Article
Open AccessClinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was th...
-
Article
Open AccessActivation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified to be r...
-
Article
Open AccessLow-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example, a ...
-
Article
Open AccessDo BRAF inhibitors select for populations with different disease progression kinetics?
Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experie...
-
Article
Open AccessPhase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 facto...
-
Chapter
Targeting Tumor Angiogenesis
Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182–1186, 1971) are becoming a reality (Verheul et al., ...
